DrugCard Simple Search

DrugCard Simple Search is a research tool. DrugCard automates pharmacovigilance literature monitoring, scanning 2,300+ local journals in 100+ languages and alerting safety teams to new drug mentions. Built for CROs, marketing authorization holders and freelancers.

DrugCard is a pharmacovigilance platform that automates the monitoring of medical literature, with a particular focus on local journals written in local languages. Instead of having safety staff read journals from cover to cover, the system scans publications for the drug names and keywords a team cares about, then alerts users when a new mention appears. The vendor states coverage of more than 100 languages, over 2,300 continuously monitored local journals and medical journal coverage across 151+ countries. The product is aimed at three groups: contract research organizations running pharmacovigilance projects for clients, marketing authorization holders that want to bring literature screening in-house, and freelancers who sell screening services. In practice, a team defines search keywords (including in non-Latin scripts such as Greek, Hindi, Arabic or Japanese), and DrugCard reads the sources, flags new drug mentions and sends an email notification right away. Weekly summary reports collect everything found in that period, which is intended to ease audits and regulatory inspections. A proprietary OCR engine handles poorly scanned printed journals, with a stated accuracy of up to 99% on average-quality scans. Adding journals for a new country typically takes two to three weeks, according to the vendor. The homepage claims 50 to 70 percent time savings against manual screening, and three to five times more hits discovered. These figures come from the vendor and customer feedback, and the company itself recommends calculating savings per project. The customer list includes a range of pharmaceutical companies and regulatory consultancies, and testimonials come from drug safety and PV professionals. Among alternatives, DrugCard mainly competes with manual screening and with outsourced CRO workflows rather than with general-purpose AI assistants. It is a specialist, sales-led service: access is arranged through a demo or meeting request, and no public pricing or self-serve sign-up is described. That makes it a fit for organizations with regulatory obligations around local literature, and a poor fit for individuals wanting a quick search utility.